Navigation Links
Valeant Pharmaceuticals Reports 2012 Third Quarter Financial Results
Date:11/2/2012

hird quarter of 2012, or $0.02 per diluted share.  On a Cash EPS basis, adjusted income was $357.5 million, or $1.15 per diluted share.  

GAAP cash flow from operations was $166.8 million in the third quarter of 2012, and adjusted cash flow from operations was $241.2 million.  Cash flow was negatively impacted by an increase in accounts receivable principally due to sequential revenue growth as compared to the second quarter, and the strong seasonal sales in the month of September, primarily in U.S. Dermatology and Europe; the Wellbutrin XL litigation settlement costs of $37.7 million; and restructuring charges from our acquisitions.  

The Company's cost of goods sold (COGS) was $219.7 million in the third quarter of 2012.  After backing out the fair value adjustment to inventory, amortization expense and other items related to acquisitions of $20.0 million, COGS represented 23% of product sales. COGS for the third quarter of 2012 were positively impacted by the strong growth in our U.S. Dermatology segment which has a lower COGS profile than other segments.

Selling, General and Administrative expenses were $188.7 million in the third quarter of 2012, which includes a $9.1 million step-up in stock based compensation expenses related to the acquisition of Legacy Valeant.  Excluding the step-up in stock based compensation, SG&A was approximately 20% of revenue. Research and Development expenses were $19.2 million in the third quarter of 2012, or approximately 2% of revenue.

2012 GuidanceThe Company is updating previous 2012 Guidance from $4.55 to $4.75 Cash EPS, or $1.25 to $1.45 Cash EPS for the fourth quarter 2012, to $4.60 - $4.65 Cash EPS, or $1.30 to $1.35 Cash EPS for the fourth quarter of 2012, which excludes the interest expense of $0.12 Cash EPS from the $2.75 billion Medicis related financing. Valeant is lowering 2012 adjusted cash flow from operations expectations from greater than $1.4 billion
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23

Related medicine technology :

1. Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical
2. Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results
3. Valeant Pharmaceuticals To Host Investor Day
4. Valeant Pharmaceuticals To Announce 2012 Second Quarter Results On August 2, 2012
5. Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash
6. Valeant Pharmaceuticals To Present At UBS Annual Global Life Sciences Conference
7. Valeant Pharmaceuticals Announces Management Change
8. Valeant Pharmaceuticals To Syndicate Incremental Loans
9. Valeant Pharmaceuticals Appoints Howard Schiller To Board Of Directors
10. Valeant Pharmaceuticals Announces Launch of Concurrent Private Offerings of Senior Notes
11. Valeant Pharmaceuticals International, Inc. Announces Pricing Of Concurrent Private Offerings Of Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015  IDEXX Laboratories, Inc. (NASDAQ: IDXX ) ... of $413 million, an increase of 6% compared to ... the US dollar reduced reported revenue growth by 7%. ... was 11%, supported by strong growth in the Companion ... ("EPS") was $0.60 for the quarter, an increase of ...
(Date:7/29/2015)... 2015  Astellas today announced topline results from ... and safety of intravenous (IV) and oral isavuconazole, ... for adults with candidemia and other invasive ... that the trial did not meet its primary ... isavuconazole-treated patients at the end of IV therapy ...
(Date:7/29/2015)... , July 29, 2015  Unilife Corporation ("Unilife" ... UNS), a developer, manufacturer and supplier of injectable drug ... financing strategy that provides the Company with flexibility and ... Unilife has signed an equity purchase agreement for ... LLC ("LPC"), a Chicago -based institutional ...
Breaking Medicine Technology:IDEXX Laboratories Announces Second Quarter Results 2IDEXX Laboratories Announces Second Quarter Results 3IDEXX Laboratories Announces Second Quarter Results 4IDEXX Laboratories Announces Second Quarter Results 5IDEXX Laboratories Announces Second Quarter Results 6IDEXX Laboratories Announces Second Quarter Results 7IDEXX Laboratories Announces Second Quarter Results 8IDEXX Laboratories Announces Second Quarter Results 9IDEXX Laboratories Announces Second Quarter Results 10IDEXX Laboratories Announces Second Quarter Results 11IDEXX Laboratories Announces Second Quarter Results 12IDEXX Laboratories Announces Second Quarter Results 13IDEXX Laboratories Announces Second Quarter Results 14IDEXX Laboratories Announces Second Quarter Results 15IDEXX Laboratories Announces Second Quarter Results 16IDEXX Laboratories Announces Second Quarter Results 17IDEXX Laboratories Announces Second Quarter Results 18IDEXX Laboratories Announces Second Quarter Results 19IDEXX Laboratories Announces Second Quarter Results 20IDEXX Laboratories Announces Second Quarter Results 21IDEXX Laboratories Announces Second Quarter Results 22IDEXX Laboratories Announces Second Quarter Results 23IDEXX Laboratories Announces Second Quarter Results 24IDEXX Laboratories Announces Second Quarter Results 25IDEXX Laboratories Announces Second Quarter Results 26IDEXX Laboratories Announces Second Quarter Results 27IDEXX Laboratories Announces Second Quarter Results 28IDEXX Laboratories Announces Second Quarter Results 29Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 2Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 3Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 4Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 5Unilife Announces Multifaceted Financing Strategy 2Unilife Announces Multifaceted Financing Strategy 3Unilife Announces Multifaceted Financing Strategy 4
... - Trial Results Confirm Efficacy for Population ... N.J. and EMERYVILLE, Calif., May 16 ,Bayer ... ONXX ) today announced that Nexavar(R) ... percent (HR=0.68;,p-value=0.014) in patients in the Asia-Pacific ...
... Ovarian ... Cancers -, - Company ... SOUTH SAN FRANCISCO, Calif., May 15 Poniard,Pharmaceuticals, Inc. (Nasdaq: ... will present data from three,clinical trials of picoplatin, in various tumor types ...
Cached Medicine Technology:Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 2Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 3Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 4Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 5Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 6Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 2Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 3Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 4Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 5
(Date:7/30/2015)... ... ... On July 23rd Clay Today Online reported the state of Florida ... system, which has amassed largely enough throughout the years. Florida is the third state ... recent reduction of non violent drug offender’s prison sentences, Florida is beginning to take ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... Gummy ... including lip lowering, gum contouring and surgery, as well as the patented gum depigmentation ... that has made him popular with many patients from around the world. , “Like ...
(Date:7/30/2015)... ... July 30, 2015 , ... New research finds some distinct differences in the ... on the Surviving Mesothelioma website. , Researchers with the National Institutes of ... 12,000 cases of mesothelioma occurring between 1990 and 2010. Two percent of these cases ...
(Date:7/30/2015)... NEW ORLEANS (PRWEB) , ... July 30, 2015 , ... ... wellbeing and take charge of their health in his new self-help book, “ Consciously ... , Llanos’ new book promotes a simple message: “If we take responsibility for ourselves, ...
(Date:7/30/2015)... ... July 30, 2015 , ... After a three year trial designed to ... commonly known as the “bionic eye,” researchers have determined the trial to be a ... patients facing or already affected by complete vision loss as a result of Retinitis ...
Breaking Medicine News(10 mins):Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 2Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 3Health News:Gummy Smile Dentist, Alex Farnoosh DMD, is Now Offering Comprehensive Treatment Options for Gummy Smiles 2Health News:Study Finds Mesothelioma Behaves Differently in Younger People, According to Surviving Mesothelioma 2Health News:New book by Dr. Raul Llanos: ‘The power to change is within’ 2Health News:New book by Dr. Raul Llanos: ‘The power to change is within’ 3Health News:The Vision Enhancing “Bionic Eye” Deemed Safe For Long Term Use After Three Year Clinical Trial 2
... support to the House of Commons vote to impose a ban ... ,A team of researchers measured the air quality, using a portable ... areas where smoking was permitted. The study revealed that the quality ... This, when inhaled, would cause harm to the health. ...
... An outbreak of cholera was first reported in the Luanda ... nearly 652 cases of cholera// and 22 cholera related deaths ... the latest health report published by the World Health Organization, ... reported over the past 24 hours. 8 municipalities have been ...
... 11-year-olds had taken a Class A drug, such as cocaine, ... taken hard drugs. There is a rise in illegal drug ... cocaine which has created a lot of trouble for the ... England's 3.4 million secondary pupils. Despite undertaking multi-million-pound campaigns such ...
... an agricultural engineer has developed a technique which uses ... serum albumin (HSA) from tobacco plants. HSA is an ... therapeutic needs. ,It is mainly used to ... attacks. It is used for haemorrhages, burns, surgical operations ...
... joined forces to create an Internet-based training programme ... degrees while continuing to work. ,The ... March, will create online courses for vets unable ... network. ,African vets urgently need extra ...
... European Breast Cancer Conference (EBCC-5) have called that patients should ... in the field. Doctors and patient groups said that women ... like Herceptin that could help prolong their survival and well ... and radiation therapy are available to women in the United ...
Cached Medicine News:Health News:Alternate ways to produce HAS from tobacco plants 2
... The SmartCycler System is a rapid, real-time ... prepared biological samples. By automating much of ... site individually programmable, it is the fastest, ... now on the market. The SmartCycler delivers ...
... The LightCycler 2.0 System is the newest ... Science. This new instrument offers six detection ... 560, 610, 640, 670, and 710nm. Perform ... by air and working with glass capillaries. ...
Mx3000P instrument, desktop computer, Mx3000P software package, user's manual, one Brilliant QPCR Reagent of your choice, and custom filter wheel with 4 filters chosen from: FAM/SYBR Green I, TET, HE...
... Stratagene delivers a new standard in QPCR ... This new system offers superior performance, more ... unit, Computer system - with Windows 98SE ... Keyboard, Mouse, Premier Sound Speakers, Surge Protector ...
Medicine Products: